Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
L03 IMMUNOSTIMULANTS
L03A IMMUNOSTIMULANTS
L03AB Interferons
L03AB15 Ropeginterferon alfa-2b
D11027 Ropeginterferon alfa-2b (INN) <JP/US>
USP drug classification [BR:br08302]
Immunological Agents
Immunostimulants
Interferons
Ropeginterferon Alfa-2b
D11027 Ropeginterferon alfa-2b (INN)
Therapeutic category of drugs in Japan [BR:br08301]
4 Agents affecting cellular function
42 Antineoplastics
429 Miscellaneous
4291 Other Antitumors
D11027 Ropeginterferon alfa-2b (INN); Ropeginterferon alfa-2b (genetical recombination) (JAN)
Drug groups [BR:br08330]
Immunological agent
DG01752 Interferone
D11027 Ropeginterferon alfa-2b
Drug classes [BR:br08332]
Immunological agent
DG01752 Interferone
D11027 Ropeginterferon alfa-2b
Target-based classification of drugs [BR:br08310]
Cytokines and receptors
Cytokine receptors
Interferon receptors
IFNAR1
D11027 Ropeginterferon alfa-2b (INN) <JP/US>
IFNAR2
D11027 Ropeginterferon alfa-2b (INN) <JP/US>
New drug approvals in the USA [br08319.html]
New molecular entities and new therapeutic biological products
D11027
New drug approvals in Europe [br08329.html]
European public assessment reports (EPAR) authorised medicine
D11027
New drug approvals in Japan [br08318.html]
Drugs with new active ingredients
D11027
New drug approvals in the USA, Europe and Japan [br08328.html]
Approval dates by FDA, EMA and PMDA
D11027